Holen Sie sich die Stockscreener-App
14.39
2.17%
0.3158
Schlusskurs vom Vortag:
$14.07
Offen:
$14.11
24-Stunden-Volumen:
764.55K
Relative Volume:
0.55
Marktkapitalisierung:
$516.76M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-168.05M
KGV:
-2.8042
EPS:
-5.13
Netto-Cashflow:
$-146.15M
1W Leistung:
+12.83%
1M Leistung:
+28.12%
6M Leistung:
-76.16%
1J Leistung:
-75.33%
1-Tages-Spanne:
$13.83
$14.67
1-Wochen-Bereich:
$12.66
$14.67
52-Wochen-Spanne:
$9.12
$72.37
Keros Therapeutics Inc Stock (KROS) Company Profile
Firmenname
Keros Therapeutics Inc
Sektor
Branche
Telefon
617-314-6297
Adresse
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Vergleichen Sie KROS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KROS
Keros Therapeutics Inc
|
14.38 | 516.76M | 0 | -168.05M | -146.15M | -5.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.89 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
559.01 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
594.73 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
229.77 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.04 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-21 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-17 | Herabstufung | Wedbush | Outperform → Neutral |
| 2024-12-16 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-12-16 | Bestätigt | Oppenheimer | Outperform |
| 2024-12-13 | Bestätigt | H.C. Wainwright | Buy |
| 2024-12-12 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-12-12 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-12-12 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-11-05 | Eingeleitet | Jefferies | Buy |
| 2024-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-09-23 | Eingeleitet | Guggenheim | Buy |
| 2024-06-25 | Eingeleitet | Oppenheimer | Outperform |
| 2024-02-21 | Eingeleitet | William Blair | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-07-31 | Eingeleitet | Wedbush | Outperform |
| 2023-07-26 | Eingeleitet | BofA Securities | Buy |
| 2023-02-14 | Eingeleitet | Cowen | Outperform |
| 2022-10-18 | Eingeleitet | Truist | Buy |
| 2022-07-26 | Eingeleitet | BTIG Research | Buy |
| 2020-12-08 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-04 | Eingeleitet | Jefferies | Buy |
| 2020-05-04 | Eingeleitet | Piper Sandler | Overweight |
| 2020-05-04 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Keros Therapeutics Inc Aktie (KROS) Neueste Nachrichten
197,666 Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) Acquired by Walleye Capital LLC - MarketBeat
Altium Capital Management LLC Has $2.77 Million Stock Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Keros Therapeutics, Inc. (NASDAQ:KROS) Major Shareholder Purchases $9,464,033.54 in Stock - MarketBeat
Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Bought by Vanguard Group Inc. - MarketBeat
Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Sold by Alliancebernstein L.P. - MarketBeat
How the (KROS) price action is used to our Advantage - news.stocktradersdaily.com
124,620 Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) Acquired by Federated Hermes Inc. - MarketBeat
Press Release Distribution & PR Platform - ACCESS Newswire
Keros Therapeutics enters agreement with Pontifax - Investing.com Australia
Keros Therapeutics enters agreement with Pontifax By Investing.com - Investing.com Canada
Norges Bank Invests $1.03 Million in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Stock Traders Purchase Large Volume of Put Options on Keros Therapeutics (NASDAQ:KROS) - MarketBeat
Truist Financial Lowers Keros Therapeutics (NASDAQ:KROS) Price Target to $25.00 - MarketBeat
Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Sold by ADAR1 Capital Management LLC - MarketBeat
KROS Initiates Exploring Strategic Alternatives, Stock Gains 18.5% - MSN
Adar1 partners increases stake in Keros Therapeutics with $9.1m purchase - Investing.com Canada
Deal Dispatch: Harley-Davidson To Wipe Out? Plus, Prada's Versace Purchase Garners A Fashionable Price - Benzinga
Keros Therapeutics: Strategic Alternatives Could Bring About Value Creation - Seeking Alpha
Keros Therapeutics (KROS) Reports Positive Phase 1 Results for K - GuruFocus
Keros Therapeutics (KROS) Shows Potential for Upside - GuruFocus
Keros Therapeutics (KROS) Surges Amid Strategic Review and Poiso - GuruFocus
Keros Therapeutics (KROS) Shows Potential with Analyst Optimism - GuruFocus
Adar1 capital management increases stake in Keros Therapeutics with $328k purchase - Investing.com
Keros Therapeutics (KROS) Initiates Strategic Review and Adopts Rights Plan | KROS Stock News - GuruFocus
Keros Therapeutics Announces Review of Strategic Alternatives | KROS Stock News - GuruFocus
Bryce Point Capital LLC Invests $445,000 in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Keros Therapeutics Explores Major Strategic Alternatives With Share Price Jump - Finimize
Keros Therapeutics Shares Rise After Board Initiates Review of Strategic Alternatives - marketscreener.com
Keros Therapeutics Goes Up For Sale On Heels Of Stockholder Rights Plan - Benzinga
Keros Therapeutics considers sale amid investor pressure - Yahoo Finance
Crude Oil Falls Over 4%; Keros Therapeutics Shares Jump - Benzinga
Keros Therapeutics Adopts Defense Strategy Against Potential Hostile Takeover, Explores Sale: Retail’s Overjoyed - MSN
Keros Therapeutics adopts poison pill as it explores options, including sale - MSN
Keros Therapeutics stock jumps on strategic review, potential sale By Investing.com - Investing.com Canada
Keros Therapeutics Considers Sale Amid Strategic Review Process - Finimize
Keros Therapeutics adopts poison pill as shareholders seek control - MSN
Keros Therapeutics Board Initiates Review of Strategic Alternatives - marketscreener.com
Keros stock climbs after strategic review (KROS:NASDAQ) - Seeking Alpha
Finanzdaten der Keros Therapeutics Inc-Aktie (KROS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.77%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):